ASBP NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Aspire BioPharma, Inc. · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 6.52 USD
-10.2% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is -74.2% below the Trend Line and sits at 0.3% of its 52-week range. The latest completed week returned -10.2%, after a 5.0% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 49/100. Near-term considerations: volume confirmation is below normal; earnings are due in 10d.

Setup score 26 out of 100
Latest Close 6.52 USD 31 Jul 2026
1W Return -10.2% latest completed week
4W Return 5.0% short-term follow-through
12W Return 17.5% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 0.0x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -10.2% Latest completed week; four-week move 5.0%. Indicator stack 0/63 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 49/100 53 relevant articles in the latest sentiment read. Event risk 10d Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -74.2% below the Trend Line and sits at 0.3% of its 52-week range. The latest completed week returned -10.2%, after a 5.0% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.0x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0812-week average 0.05

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.08Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 5.0% over four weeks, 17.5% over 12 weeks, and -98.5% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-10.2%
4W5.0%
12W17.5%
26W-89.8%
52W-98.5%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.70Latest activity-pressure read.
Pressure change2.7%Four-week change in activity pressure.
Leadership-96.52Latest relative-leadership reading.
RS change0.9%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 79% Model confidence 76%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength72/100Blend of value, momentum, and quality. Underlying universe rank 29; rank 1 is best.
Value61/100Relative valuation strength. Underlying universe rank 40; rank 1 is best.
Quality59/100Profitability and accounting quality. Underlying universe rank 42; rank 1 is best.
Momentum61/100Medium-term price momentum. Underlying universe rank 40; rank 1 is best.
Growth61/100Revenue and earnings growth. Underlying universe rank 40; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
272.1x
Market value relative to trailing revenue.
EV / EBITDA
1.2x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-123.1%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-0.3%
Gross profit retained from each unit of revenue.
Operating margin
-13502.9%
Operating profit retained from revenue.
Free-cash-flow margin
-17972.7%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-2.8%
Net share repurchases relative to market value.
Shareholder yield
-2.8%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-1.0x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment49/100

Weighted news tone is neutral across 53 relevant articles.

6 positive · 40 neutral · 7 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings10dNext report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-99.4%Distance below the 52-week high.
13-week volatility11.7%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher10 of 2615 weeks finished lower.
Best week+32.7%Week of 19 Jun.
Worst week-74.6%Week of 17 Apr.
Latest week-10.2%Week of 31 Jul.

Shape of recent returns

Strong gains4
Modest gains6
Flat weeks1
Modest losses5
Sharp losses10
Recent vol11.7%13-week weekly-return volatility.
Base vol20.9%52-week weekly-return volatility.
Up/down split23/28Count of positive and negative weeks in the 52-week window.
Average skew11.2% / -18.1%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape20/100

Trend, activity pressure, participation, and risk combine to a 20/100 tape read.

 Indicator analysis31/100

Latest 12-week confirmation: trend 0/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.08; No reversal markers Factors63/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 80 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment49/100

Weighted news tone is neutral across 53 relevant articles.

Aspire Biopharma Holdings Inc (ASBP) Earnings Forecast: Future EPS & Revenue Growth Estimates Insiders50/100

No recent insider transaction evidence is stored.

 Earnings10d

Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20266.52 USD-10.2%25.28 USD7,071 USD0.70-96.52184.5KOff
24 Jul 20267.26 USD16.3%30.53 USD7,153 USD0.55-96.31393.4KOff
17 Jul 20266.24 USD3.8%34.61 USD7,233 USD0.50-97.08239.6KOff
10 Jul 20266.01 USD-3.2%38.31 USD7,314 USD0.62-97.43265.0KOff
3 Jul 20266.21 USD3.5%41.91 USD7,395 USD0.69-97.41495.5KOff
26 Jun 20266.00 USD-8.8%45.36 USD7,475 USD0.64-97.56382.2KOff
19 Jun 20266.58 USD32.7%49.39 USD7,555 USD0.49-97.531.4MOff
12 Jun 20264.96 USD-7.1%53.07 USD7,635 USD0.37-98.1513.2MOff
5 Jun 20265.34 USD-2.7%57.15 USD7,716 USD0.30-98.05403.7KOff
29 May 20265.49 USD1.5%66.58 USD7,796 USD0.33-98.161.3MOff
22 May 20265.41 USD-3.6%81.70 USD7,876 USD0.47-98.225.8MOff
15 May 20265.61 USD1.1%95.29 USD7,956 USD0.63-98.17806.2KOff
8 May 20265.55 USD-12.8%108.7 USD8,035 USD0.67-98.24204.8MOff
1 May 20266.37 USD3.5%121.7 USD8,116 USD0.61-97.95270.4MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.